NEONATAL SCREENING FOR INBORN ERRORS OF METABOLISM OUR EXPERIENCE AT CABRI, GULF MEDICAL UNIVERSITY
|
|
- Peregrine Fleming
- 5 years ago
- Views:
Transcription
1 GMJ GULF MEDICAL JOURNAL ORAL PROCEEDINGS NEONATAL SCREENING FOR INBORN ERRORS OF METABOLISM OUR EXPERIENCE AT CABRI, GULF MEDICAL UNIVERSITY I.A. Shaafie 1 *, A.D. Vijay Raju 2, P.K. Menon 3 1Division of Clinical Biochemistry, 2 Analytical Chemistry, 3 Clinical Microbiology, Molecular Biology, Centre for Advanced Biomedical Research and Innovation (CABRI), Gulf Medical University, Ajman, UAE *Presenting Author ABSTRACT Neonatal screening is a vital process that identifies apparently healthy neonates with serious inherited disorders, which are generally metabolic in origin and correctable by dietary or drug interventions. Inborn errors of metabolism are rare in isolation, but collectively are common. They usually present in the neonatal period or infancy, but can occur at any time, even in adulthood. The purpose of this study is to review the results of a comprehensive newborn screening panel of 57 biochemical parameters measured in 4,408 dried blood spot samples collected hours after birth by the heelprick method. The samples were analyzed using tandem mass spectrometry (LC-MS/MS), cation exchange chromatography, and the DELFIA time-resolved fluorescence (TRF) intensity technology. All the assays were validated and well controlled. Proficiency testing samples from the Centers of Disease Control and Prevention (CDC) were run along with the neonatal samples. The cut-off values used for various parameters were validated and found to be acceptable. The results showed that glucose-6-phosphate was the most common disorder (93 cases), followed by hemoglobinopathies (27 cases), congenital hypothyroidism (24 cases), cystic fibrosis (22 cases), and congenital adrenal hyperplasia (7cases). The overall incidence rate of inborn errors of metabolism was 4.31%, marginally higher than the national figures of the UAE. The types of disorders detected are identical to those found in surveys conducted in the UAE and other countries. In view of the high prevalence of genetic and metabolic disorders detected by the study, neonatal screening should be made mandatory in the UAE. This would enable early detection and management of genetic and metabolic disorders, and reduce the number of physically and mentally challenged children in the community. The role of governments, by providing administrative and financial support, is crucial for successful implementation of the neonatal screening program. Keywords: Neonatal screening, dried blood spots, inborn errors of metabolism, tandem mass spectrometry, DELFIA TRF technique, Newborn Screening Quality Assurance Program, cation exchange Citation: Shaafie IA, Raju ADV, Menon PK. Neonatal screening for inborn errors of metabolism our experience at CABRI, Gulf Medical University. Gulf Medical Journal. 2016;5(S1):S35 S42. INTRODUCTION Neonatal screening (NNS) is the practice of testing every newborn for certain genetic, endocrine, and metabolic disorders that are Correspondence: Dr. Ishtiyaq Ahmad Shaafie (MD, PGDHPE), Specialist Clinical Biochemist, CABRI, Gulf Medical University, UAE. piashaafie@gmu.ac.ae typically not apparent at birth. All these disorders, except congenital deafness and critical congenital heart diseases, are detected by dry blood spot (DBS) screening. Inborn errors of metabolism (IEM) are a major group of heterogeneous monogenic disorders commonly identified by NNS. When dietary restriction or drug therapy is used at an early age, morbidity and mortality due to IEM are reduced 1. Any delay in the diagnosis and treatment leads to 35
2 I.A. SHAAFIE, ET AL adverse outcomes, including neuropsychological dysfunction, mental retardation, and ultimately death 2. Dr. Robert Guthrie, an American bacteriologist and physician, was the first to develop a test to detect phenylketonuria in 1960 for his own child 3. Later, Guthrie and his colleagues used tests to detect congenital hypothyroidism, maple syrup urine disease (MSUD), and classic galactosemia. In 1968, the World Health Organization (WHO) provided guidelines for screening of newborns for specific disorders using the 10 criteria of Wilson and Jungner 4. However, the introduction of tandem mass spectrometry (MS/MS) in early 1990 and its ability to simultaneously measure numerous metabolites changed the old concept about NNS as one test for one disorder to one test for many disorders, i.e., a multiplex test 5. The WHO guidelines have been revised, and a number of new disorders that could be detected from a single sample have been added to the list. This expanded newborn screening has led to the detection of disorders for which there is currently no treatment. However, NNS helps families/relatives by providing early diagnosis for the neonate and planning for future pregnancies 6, 7. In 2006, the Advisory Committee on Heritable Disorders in Newborns and Children from the US Department of Health Resources and Services Administration (HRSA) recommended a uniform screening panel of 29 core (primary) and 25 secondary disorders among neonates for all US states on the basis of scientific and medical evidence from the American College of Medical Genetics and the American Academy of Pediatrics. Of these 54 disorders, 42 can be detected by MS/MS, while others, such as hemoglobinopathies, congenital hypothyroidism, congenital adrenal hyperplasia, biotinidase deficiency (BIOT), galactosemia, cystic fibrosis, and congenital hearing loss, are detected using other methods. The National Academy of Clinical Biochemistry has categorized the strengths of recommendations for the adoption of MS/MS for IEM 8. False positive results and relatively poor positive predictive values for some MS/MS tests have led to the development of second-tier tests that require separate testing protocols 9, 10. NNS has been adapted as a coordinated comprehensive public health program in the US, Canada, and several European countries. These programs involve education, screening, detection, and follow-up of abnormal and unsatisfactory results; confirmation of positive results; treatment and follow-up of neonates with genetic disorders; quality assurance and program evaluation; validation of testing systems; and assessment of long-term benefits to the patients, families, and society. Most developing countries do not have a government-funded preventive public health program for NNS, resulting in many cases of inherited disorders going undetected among the population. In 1995, a national NNS program was established in the UAE for early identification and treatment of IEM, so as to prevent morbidity and mortality due to these disorders. The program started with initial screening for phenylketonuria and was made comprehensive in Centre for Advanced Biomedical Research and Innovation (CABRI) at Gulf Medical University started NNS in January 2015, providing a comprehensive screening panel for 57 biochemical and hematological genetic disorders. The current study reviews the outcomes of this screening, and summarizes the validation process for establishing reference ranges of all 57 analytes using the LC-MS/MS and dissociationenhanced lanthanide fluorescence immunoassay (DELFIA ) techniques. MATERIALS & METHODS Blood Specimens DBS samples were collected at Thumbay Hospitals and other clinics from 4,408 apparently healthy neonates hours after birth with parental consent. The samples were collected by the heel-prick method using standard Whatman 903 TM Specimen Collection cards from GE Healthcare, USA. All guidelines for collection, transport, and processing of samples were followed. 36
3 NEONATAL SCREENING FOR INBORN ERRORS OF METABOLISM OUR EXPERIENCE AT CABRI, GMU Methodology The DBS samples were analyzed for various biochemical and hematological parameters using LC-MS/MS with electrospray ionization (ESI), DELFIA [a time-resolved fluorescence (TRF) intensity technology], and cation exchange HPLC techniques (refer Tables 1 3). The test results were checked for precision and accuracy using the quality control materials provided by the kit manufacturers for HPLC and DELFIA assays. All the results were found to be precise and accurate. Table 1. Amino acid disorders detected by LC-MS/MS Biomarker Phenyl alanine Phenyl alanine/tyrosine ratio Arginine Citrulline Valine/leucine/isoleucine Disorder(s) related Phenylketonuria (PKU) Argininemia/arginase deficiency Citrullinemia (argininosuccinic acid synthetase deficiency) Maple syrup urine disease (MSUD) Table 2. Acylcarnitine/fatty acid disorders detected by LC-MS/MS Biomarker C3 C3-DC + C4-OH C4 C4-DC + C5-OH C4 & C5 C5 C5-DC + C6-OH C0 C6, C8, C8/C10 ratio, C10:1 C14, C14:1 C14:1 C14-OH C18 Disorder(s) Propionic acidemia Methyl malonic acidemia Malonic aciduria Short-chain acyl-coa Methylmalonic acidemia Methylmalonic acidemia with B12 defect and homocystinuria Ethylmalonic encephalopathy Isovaleric acidemia Glutaric acidemia type I Carnitine transporter deficiency Medium chain acyl-coa (MCAD deficiency) Very long-chain acyl-coa Multiple acyl-coa (MAD deficiency)/glutaric acidemia type II (GA-2) Long-chain hydroxyacyl-coa Very long-chain acyl-coa Table 3. Disorders detected by DELFIA and HPLC (cation exchange) techniques Biomarker Disorder(s) Glucose-6-phosphate Glucose-6-phosphate dehydrogenase dehydrogenase (G6PD) deficiency Immunoreactive trypsinogen (IRT) Cystic fibrosis 17-hydroxy progesterone (17-OH-P) Congenital adrenal hyperplasia Thyroid stimulating hormone (htsh) Congenital hypothyroidism Thyroxine (T4) Congenital hypothyroidism Galactose-1-phosphate uridyl transferase (GALT) Classic galactosemia Biotinidase BIOT Disorders detected by HPLC Hemoglobinopathies HbS, HbC, HbD Cut-off Values The cut-off values for our tests were adapted from the kit inserts; operation manuals of the analyzers; NeoGen Labs (India); California Department of Public Health s cutoff/reference ranges for acylcarnitines and amino acids; and reference ranges used at the Biochemical Genetics Laboratory, King Faisal Specialist Hospital & Research Centre, Saudi Arabia. Quality Control Internal quality control tests were run with each batch of tests. The results were evaluated for acceptable criteria. According to the requirements of the College of American Pathologists (CAP) for alternate proficiency testing, CABRI s laboratory participates in the Newborn Screening Quality Assurance Program (NSQAP) run by the Centers of Disease Control and Prevention (CDC), USA. The results showed 100% accuracy for 2015 and 2016 (Table 4). Ethical Issues All samples were collected after parental consent. The data presented is from deidentified samples. 37
4 I.A. SHAAFIE, ET AL Table 4. NSQAP - Year: 2015 (Cycles: 3 and 4) and 2016 (Cycle 1) Sr. No. Component No. of analytes Total no. of challenges per cycle Cycle Cycle Cycle No. of challenges passed Accuracy (%) Acceptable limit 1 Acylcarnitines % 80% 2 Amino acids % 80% 3 GALT % 80% 4 IRT % 80% 5 BIOT % 80% 6 Hormones % 80% Total RESULTS & DISCUSSION The biomarkers of IEM detected by various techniques are depicted in Tables 1 3. The results show that the majority of neonates (62%) observed were from South Asia, followed by East Asia, the Middle East, and Africa. (Figure 1). This indicates the ethnic background of the patients who usually visit Thumbay Hospitals. The cut-off values used for 57 analytes were internally verified by 80 randomly collected normal DBS samples. The mean and median values were calculated for each analyte. The calculated values were below the cut-off limits, found to be acceptable, and adopted (Tables 5 7). Tables 8 and 9 display the genetic and metabolic disorders identified, and ethnic and gender distribution of these disorders, respectively. G6PD deficiency was the most common disorder (2.1%), followed by hemoglobinopathies (0.61%), congenital hypothyroidism (0.54%), and cystic fibrosis (0.50%). The findings of a hospital-based study conducted by Saleh et al. on 15,995 cases at Abu Dhabi for the molecular characterization of G6PD deficiency showed that the deficiency was prevalent in both UAE (7.4%) and non- UAE nationals (3.8%), while the Mediterranean mutation, 563C T, was predominant among non-uae nationals 12. G6PD is not a part of the UAE s National Newborn Screening Program, although the Health Authority of Abu Dhabi (HAAD) included the condition in its comprehensive screening panel in Figure 1. Ethnic distribution of neonates subjected to DBS analysis 2, South East Asians Asians (China, (India, Philippines) Pakistan, Bangladesh, Sri Lanka) Number of samples Table 5. Verification of amino acid cut-off values using LC-MS/MS Analyte Mean Median Cut-off value (µmol/l) Glycine ,000 Alanine Valine Leucine-isoleu Ornithine Aspartic acid Methionine Phenyl alanine Citrulline Tyrosine Proline Glutamic acid ,074 Arginine Arabs Africans Europeans 38
5 NEONATAL SCREENING FOR INBORN ERRORS OF METABOLISM OUR EXPERIENCE AT CABRI, GMU Table 6. Verification of acylcarnitine/fatty acid cut-off values Analyte Mean Median Cut-off value (µmol/l) C C C C C C C5DC C C C C C C C5: C5-OH C8: C10: C14: C14-OH C16: C16-1OH C16-OH C18: C18:1OH C18-OH Table 7. Verification of cut-off values of neonatal biochemical parameters measured using DELFIA TRF technique Analyte Unit Mean Median Cut-off value 17-OH progesterone nmol/l >29.9 borderline high ; >89.9 very high G6PD U/g Hb borderline deficient; 2.2 highly deficient Thyrotropin µu/ml >9.9 borderline high; >24.9 very high IRT ng/ml >40 borderline high; >80 very high Gal-1-phosphate uridyl transferase U/gHb borderline low; 2.4 very low Biotinidase U Thyroxine nmol/l deficient 75 borderline deficient; 25 highly deficient 39
6 I.A. SHAAFIE, ET AL Table 8. Gender Distribution of genetic and metabolic disorders among neonates Disorder Gender Male (N = 2,165) Female (N = 2,243) G6PD deficiency 84 9 Hemoglobinopathies (HbC 4, HbS 12, HbD 11) Congenital hypothyroidism 17 7 Cystic fibrosis 9 13 Congenital adrenal hyperplasia 4 3 BIOT 2 4 Phenylketonuria 1 1 Tyrosinemia - 2 Propionic acidemia/methylmalonic acidemia - C3 1 1 MSUD 1 - Glutaric acidemia type II - C4 1 - MCAD deficiency - C8 1 - Isovaleric acidemia - C5 1 - Classical galactosemia 1 - Positive cases (Total) Positive cases (%) Table 9. Prevalence of genetic disorders among neonates by ethnicity Disorder South Asians (N = 2,742) East Asians (N = 516) Ethnicity Arabs (N = 895) Africans (N = 221) Europeans (N = 34) G6PD deficiency Hemoglobinopathies Congenital hypothyroidism Cystic fibrosis Congenital adrenal hyperplasia BIOT Phenylketonuria Tyrosinemia Propionic acidemia/ methylmalonic acidemia MSUD Glutaric acidemia type II MCAD deficiency Isovaleric acidemia Classical galactosemia Total no. of positive cases % of positive cases
7 NEONATAL SCREENING FOR INBORN ERRORS OF METABOLISM OUR EXPERIENCE AT CABRI, GMU Currently, the UAE s National Newborn Screening Program includes the following 16 disorders: congenital hypothyroidism; sickle-cell disease; congenital adrenal hyperplasia; BIOT; and 12 amino acid, organic acid, and fatty acid disorders. Al Hosani et al. analyzed the data of NNS from January 1995 to December 2011; the results showed that the prevalence of screened disorders was 1:1,873 for congenital hypothyroidism; 1:14,544 for phenylketonuria; 1:3,526 for amino acid, organic acid, and fatty acid disorders; 1:9,030 for classical congenital adrenal hyperplasia; 1:8,300 for BIOT; 1:2,384 for sickle-cell disease; and 1:121 for sickle-cell traits 11. About 95% neonates were screened in the UAE in Although the sample size of our study is small, the results obtained are in line with the national figures. The findings of our study showed that 22 cases had high IRT activity, the most likely feature of cystic fibrosis. Some of these cases were confirmed positive for cystic fibrosis at Tawam Hospital, UAE. NNS is still not mandatory in the UAE, although HAAD has made it compulsory for all hospitals in Abu Dhabi to screen all newborns delivered in their facilities. The Ministry of Health and Dubai Health Authority hospitals perform free NNS for Emiratis. Private hospitals offer screening to their clients at a price, and the panel offered is not uniform. The barriers for uniform NNS in the UAE are high cost for NNS, improper treatment and followup of positive cases, births occurring at places other than hospitals, improper sample collection due to the lack of proper training, lack of knowledge among parents about the importance of screening, and difficulty in contacting parents in remote areas. CONCLUSION The results of our study showed that the prevalence of IEM among neonates was high, dominated by G6PD deficiency, hemoglobinopathies, and cystic fibrosis. Considering the rising incidences of genetic and metabolic disorders globally, and benefits of early diagnosis and treatment of affected neonates, it is imperative to screen every newborn for early detection of any congenital, genetic, or metabolic disorder to prevent any mental or physical derangement if the baby survives. Lack of knowledge about these disorders and inadequate facilities for LC- MS/MS at many hospitals in the UAE result in numerous cases of IEM in neonates going undetected, causing serious health issues. CABRI provides comprehensive testing and evaluation of 57 disorders using state-of-the-art technology for specimen analysis. Currently, the main limitation of our screening program is the inability to follow-up with neonates; this requires a concerted effort by the healthcare team comprising the obstetrician, neonatologist, pediatrician, educators, counselors, and parents. However, given the challenges and opportunities, screening itself is not enough. It is important to avoid complacency in assuming that every newborn who is screened positive would receive optimal service and care, irrespective of the lack of financial resources. Short-term follow-up and management of children with disorders, and long-term followup activities within the entire newborn screening system are crucial for an effective NNS program. In general, some factors that would make the newborn screening program successful and sustainable are government prioritization, full or partial government financing, public education and acceptance, cooperation of health practitioners, and institutionalization of the program. REFERENCES 1. Chen B, Mei J, Kalman L, Shahangian S, Williams I, Gagnon MB, et al. Good laboratory practices for biochemical genetic testing and newborn screening for inherited metabolic disorders. MMWR Recomm Rep. 2012;61(RR-2): Zhang C, Xu K, Dave UP, Wang Y, Matsumoto I. Inborn errors of metabolism discovered in Asian department of pediatrics and mental retardation research center. J Chromatogr B Biomed Sci Appl. 2000;746(1): Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in 41
8 I.A. SHAAFIE, ET AL large populations of newborn infants. Pediatrics. 1963;32: Wilson JM, Jungner YG. [Principles and practice of mass screening of disease]. Bol Officina Sanit Panam. 1968;65: Spanish. 5. Millington DS, Kodo N, Terada N, Roe D, Chace DH. The analysis of diagnostic markers of genetic disorders in human blood and urine using tandem mass spectrometry with liquid secondary ion mass spectrometry. International Journal of Mass Spectrometry and Ion Processes.1991;111: Pitt JJ. Newborn screening. Clin Biochem Rev. 2010;31(2): Watson MS, Mann MY, Lloyd-Puryear MA, Rinaldo P, Howell RR. Newborn screening: toward a uniform panel and system: executive summary. Genet Med. 2006;8 Suppl 1:1S 11S. 8. Dietzen DJ, Rinaldo P, Whitley RJ, Rhead WJ, Hannon WH, Garg UC, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: follow-up testing for metabolic disease identified by expanded newborn screening using tandem mass spectrometry; executive summary. Clin Chem. 2009;55(9): Oglesbee D, Sanders KA, Lacey JM, Magera MJ, Casetta B, Strauss KA, et al. Second-tier test for quantification of alloisoleucine and branched-chain amino acids in dried blood spots to improve newborn screening for maple syrup urine disease (MSUD). Clin Chem. 2008;54(3): Matern D, Tortorelli S, Oglesbee D, Gavrilov D, Rinaldo P. Reduction of the false-positive rate in newborn screening by implementation of MS/MS-based secondtier tests: the Mayo Clinic experience ( ). J Inherit Metab Dis. 2007;30(4): Al Hosani H, Salah M, Osman HM, Farag HM, El-Assiouty L, Saade D, et al. Expanding the comprehensive national neonatal screening programme in the United Arab Emirates from 1995 to East Mediterr Health J. 2014;20(1): Bin Amro SA, Al Zaabi E, Hussain S, Aly AM, Baqir HS, Ahmed Zaki AH, et al. Molecular characterization of glucose-6- phosphate in Abu Dhabi District, United Arab Emirates. Tropical Journal of Pharmaceutical Research. 2014;13(5):
HA Convention 2016 Master course How to Handle Abnormal Newborn Metabolic Screening Results Causes, Management and Follow up
HA Convention 2016 Master course How to Handle Abnormal Newborn Metabolic Screening Results Causes, Management and Follow up Dr. Josephine Chong Clinical Professional Consultant Centre of Inborn Errors
More informationScreening Newborns for Congenital Disorders
Screening Newborns for Congenital Disorders Gary L. Hoffman, BS; Ronald H. Laessig, PhD ABSTRACT The Newborn Screening Laboratory at the Wisconsin State Laboratory of Hygiene (WSLH) tests all newborn babies
More informationNewborn Screening: Focus on Treatment
Newborn Screening: Focus on Treatment Alan R. Fleischman, M.D. Senior Vice President and Medical Director March of Dimes National Conference of State Legislatures July 21, 2008 Newborn Screening: A Public
More informationPositive Newborn Screens: What do you do next?
Positive Newborn Screens: What do you do next? James B. Gibson, MD, Ph.D. Biochemical Geneticist at Specially for Children Clinical Associate Professor of Pediatrics UTHSCSA Carla R. Scott, MD Pediatric
More informationOverview of Newborn Screening, Potential Uses of Residual Dried Blood Spots, and Protection of Privacy
Overview of Newborn Screening, Potential Uses of Residual Dried Blood Spots, and Protection of Privacy Alan R. Fleischman, M.D. Senior Vice President and Medical Director Chair, Federal Advisory Committee,
More informationLab Guide 2019 Metabolic Section Lab Guide
Lab Guide 2019 Metabolic Section Lab Guide Quantitative Amino acids Plasma Plasma. Container/Tube: Preferred EDTA, Place immediately in ice. Acceptable: lithium heparin, sodium heparin. Patient preparation:
More informationRoutine Newborn Screening, Testing the Newborn Inherited Metabolic Disorders Update August 2015
Routine Newborn Screening, Testing the Newborn Inherited Metabolic Disorders Update August 2015 Metabolic birth defects can cause physical problems, mental retardation and, in some cases, death. It is
More informationA Guide for Prenatal Educators
A Guide for Prenatal Educators Why Teach Newborn Screening This booklet is designed to make it easy for you, a prenatal educator, to effectively inform expectant parents about newborn screening. All of
More informationNEWBORN METABOLIC SCREEN, MINNESOTA
Lab Dept: Test Name: Chemistry NEWBORN METABOLIC SCREEN, MINNESOTA General Information Lab Order Codes: Synonyms: CPT Codes: Test Includes: PKUN Newborn Screen for Hyopothyroidism, Phenylketonuria (PKU),
More informationTitle: Assessing Recommendations Related To Timeliness of Newborn Screening
Title: Assessing Recommendations Related To Timeliness of Newborn Screening Purpose: In January 2014, the Secretary s Discretionary Advisory Committee on Heritable Diseases on Newborns and Children (Committee)
More informationNewborn Screening & Methods for Diagnosing Inborn Errors of Metabolism
Newborn Screening & Methods for Diagnosing Inborn Errors of Metabolism Patricia Jones, PhD DABCC FACB UT Southwestern Medical Center Children s Medical Center Dallas, Texas Learning Objectives Justify
More informationFor Your Baby s Health Department of Health
Newborn Screening For Your Baby s Health Department of Health Why is my baby tested? To help make sure your baby will be as healthy as possible. The blood test provides important information about your
More informationConsiderations in Choosing Screening Conditions: One (US) Approach
22 Plenary Considerations in Choosing Screening Conditions: One (US) Approach Bradford L Therrell Jr, 1,2 MS, PhD Abstract The lack of a national policy on newborn screening (NBS) in the United States
More informationHow MS/MS Revolutionized Newborn Screening
How MS/MS Revolutionized Newborn Screening David S Millington, PhD Medical Research Professor of Pediatrics Director, Biochemical Genetics Laboratory Duke University Medical Center NEWBORN SCREENING IN
More information(f) "Birthing center" means any facility that is licensed by the Georgia Department of Community Health as a birthing center;
Ga. Comp. R. & Regs. r. 511-5-5-.02 Definitions Rule 511-5-5-.02. Definitions (a) "Abnormal test result" is a test result from blood testing or physiologic monitoring that is outside the screening limits
More informationNewborn Screening in Washington State Saving lives with a simple blood spot
Newborn Screening in Washington State Saving lives with a simple blood spot Ashleigh Ragsdale, MPH Gauri Gupta, MScPH Objectives Newborn Screening Overview Process and Law Completing Collection Cards Video
More informationThe Compelling Benefits of Routine 2 nd NBS: A Fifteen-Year Review in Washington State. Saving lives with a simple blood spot
The Compelling Benefits of Routine 2 nd NBS: A Fifteen-Year Review in Washington State Caroline T. Nucup-Villaruz, MD Primary Author NBS Consultant - Disorder FU Santosh Shaunak Co-Author & Presenter Laboratory
More informationSelective newborn screening of amino acid, fatty acid and organic acid disorders in the Kingdom of Bahrain.
Selective newborn screening of amino acid, fatty acid and organic acid disorders in the Kingdom of Bahrain. Jamal Golbahar PhD Associate Professor of Molecular Medicine, Department of Molecular Medicine,
More informationNewborn Screening: Blood Spot Disorders
Newborn Screening: Blood Spot Disorders Arizona s Newborn Screening Program Program Overview Panel of Disorders Disorder Descriptions Program Components Hospitals ADHS Lab ADHS Follow-up ADHS Billing Medical
More informationTIMELINESS OF NEWBORN SCREENING: RECOMMENDATIONS FROM ADVISORY COMMITTEE ON HERITABLE DISORDERS IN NEWBORNS AND CHILDREN
TIMELINESS OF NEWBORN SCREENING: RECOMMENDATIONS FROM ADVISORY COMMITTEE ON HERITABLE DISORDERS IN NEWBORNS AND CHILDREN Susan Tanksley, PhD May 19, 2015 TIMELINESS - BACKGROUND In order to effectively
More informationMost common is the congenital adrenogenital syndrome (AGS) or congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency.
Newborn Screening Examination parameters: TSH-neonatal (hypothyreosis), 17-OH progesterone (AGS), galactose (galactosemia), galactose-uridyl transferase (galacto semia), biotinidase (biotinidase ), phenylalanine
More informationNewborn Screening in Manitoba. Information for Health Care Providers
Newborn Screening in Manitoba Information for Health Care Providers Newborn screening: a healthy start leads to a healthier life Health care professionals have provided newborn screening for phenylketonuria
More information[R23-13-MET/HRG] STATE OF RHODE ISLAND AND PROVIDENCE PLANTATIONS DEPARTMENT OF HEALTH. February October October 1992 (E) September 1995
RULES AND REGULATIONS PERTAINING TO THE NEWBORN METABOLIC, ENDOCRINE, AND HEMOGLOBINOPATHY SCREENING PROGRAM AND THE NEWBORN HEARING LOSS SCREENING PROGRAM [R23-13-MET/HRG] STATE OF RHODE ISLAND AND PROVIDENCE
More informationAnalytes, instrumentation and software for neonatal screening. Complete solutions for screening newborns
Analytes, instrumentation and software for neonatal screening Complete solutions for screening newborns w w w. p e r k i n e l m e r. c o m 1 Everything you need for efficient neonatal screening PerkinElmer
More informationAttachment 1. Newborn Screening Program Description
Attachment 1 Newborn Screening Program Description The core mission of Texas Newborn Screening Program is to save children s lives through the early detection of life-threatening disorders. 34 Newborn
More informationNewborn Screening: What s New?
Newborn Screening: What s New? Patricia M. Jones, PhD (Department of Pathology, University of Texas Southwestern Medical Center and Children s Medical Center of Dallas, Dallas, TX) DOI: 10.1309/LMOOXWVPSM5FC3B6
More informationAnnual Report on the External Quality Assessment Scheme for Biochemical Genetics in Korea (2014)
ANNUAL REPORT http://dx.doi.org/10.15263/jlmqa.2015.37.2.56 Annual Report on the External Quality Assessment Scheme for Biochemical Genetics in Korea (2014) Soo-Youn Lee 1, Ok Ja Ji 1, Gye Cheol Kwon 2,
More informationMost common metabolic disorders in childhood. Neonatal screening and diagnostic approach to the. Inborn errors of metabolism (IEM)
Department of Pediatrics and Developmental Disorders Medical University of Bialystok Most common metabolic disorders in childhood. Neonatal screening and diagnostic approach to the inborn errors of metabolism
More informationNEWBORN SCREENING. in Massachusetts: Answers for You and Your Baby. University of Massachusetts Medical School
University of Massachusetts Medical School NEWBORN SCREENING in Massachusetts: Answers for You and Your Baby New England Newborn Screening Program Biotech 4, 2nd Floor UMass Medical School 377 Plantation
More informationThe spectrum and outcome of the. neonates with inborn errors of. metabolism at a tertiary care hospital
The spectrum and outcome of the neonates with inborn errors of metabolism at a tertiary care hospital Dr. Sevim Ünal Neonatology Division, Ankara Children s Hematology Oncology Research Hospital, Ankara,
More informationINBORN ERRORS OF METABOLISM (IEM) IAP UG Teaching slides
INBORN ERRORS OF METABOLISM (IEM) 1 OBJECTIVES What are IEMs? Categories When to suspect? History and clinical pointers Metabolic presentation Differential diagnosis Emergency and long term management
More informationNewborn Bloodspot Screening Information for parents
Newborn Bloodspot Screening Information for parents You will be offered a bloodspot screening test for your newborn baby for several rare but serious conditions. The sample for this test is usually taken
More informationXiaolei Xie, Marta Kozak. Thermo Fisher Scientific, 355 River Oaks Parkway, San Jose, CA Introduction
Comparison of Non-derivatization and Derivatization Tandem Mass Spectrometry Methods for Analysis of Amino Acids, Acylcarnitines, and Succinylacetone in Dried Blood Spots Xiaolei Xie, Marta Kozak Thermo
More informationNewborn Bloodspot Screening Information for parents
Newborn Bloodspot Screening Information for parents You will be offered a bloodspot screening test for your newborn baby for several rare but serious conditions. The sample for this test is usually taken
More informationSo Much More Than The PKU Test
Newborn Metabolic Screening So Much More Than The PKU Test Sarah Viall, MSN, PPCNP BC Newborn Screening Program Coordinator Division of Genetics & Metabolism Conflicts of Interest I have no conflicts of
More informationGUIDE TO NEWBORN SCREENING PROGRAMME
\ GUIDE TO NEWBORN SCREENING PROGRAMME 1 MEDILAB PROFILE MEDILAB, the leading independent provider of Clinical Laboratory Diagnostic Services in Cyprus, was established in 1980 by Mr. C. Pavlides and has
More informationBeyond the case for NBS in South Africa. Chris Vorster 28/05/2016
Beyond the case for NBS in South Africa Chris Vorster 28/05/2016 The case for NBS in SA Economic justification Cost Utility analysis = Cost/QALY GDP/Capita Immediate implementation (WHO) Political justification
More informationNEWBORN SCREENING IN JAPAN
NEWBORN SCREENING IN JAPAN Kikurnaro Aoki KagawaNutrition University, Saitama, Japan Abstract. In the 19701s, the government began to take steps for the treatment of congenital diseases. Mass newborn screening
More informationComprehensive cost-utility analysis of newborn screening strategies Carroll A E, Downs S M
Comprehensive cost-utility analysis of newborn screening strategies Carroll A E, Downs S M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 12/19/17 SECTION: MEDICINE LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:
MEDICAL FOODS Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are
More informationNewborn Screening: Past, Present and the Future
The Hong Kong College of Pathologists, Incorporated in Hong Kong with Limited Liability Volume 11, Issue 2 August 2016 Editorial note: In this topical update, Dr Chloe Mak reviews the history and development
More informationUse of a Tandem Mass Spectrometry Research Method for the Analysis of Amino Acids and Acylcarnitines in Dried Blood Spots
Use of a Tandem Mass Spectrometry Research Method for the Analysis of Amino Acids and Acylcarnitines in Dried Blood Spots Xiaolei Xie and Marta Kozak Thermo Fisher Scientific, San Jose, CA, USA Application
More informationTandem Mass Neonatal Screening in Taiwan Report from One Center
ORIGINAL ARTICLE Tandem Mass Neonatal Screening in Taiwan Report from One Center Hsiang-Po Huang, 1,2 Kai-Lin Chu, 1 Yin-Hsiu Chien, 1,3 Ming-Lee Wei, 3 Shu-Tzu Wu, 3 Shiao-Fang Wang, 3 Wuh-Liang Hwu 1,3
More informationHealth Chapter ALABAMA STATE BOARD OF HEALTH ALABAMA DEPARTMENT OF PUBLIC HEALTH BUREAU OF FAMILY HEALTH SERVICES ADMINISTRATIVE CODE
ALABAMA STATE BOARD OF HEALTH ALABAMA DEPARTMENT OF PUBLIC HEALTH BUREAU OF FAMILY HEALTH SERVICES ADMINISTRATIVE CODE CHAPTER 420-10-1 CARE AND TREATMENT OF INFANTS IDENTIFIED THROUGH THE NEWBORN SCREENING
More informationReliable. results. efficiently. for CH, galactosemia, CAH and CF screening
GSP Neonatal assays for CH, galactosemia, CAH and CF screening Reliable results efficiently GSP Neonatal kits DELFIA or enzyme-based fluorescence assays GSP is the new, automated neonatal screening system
More informationSequencing in Newborn Screening Introduction and Background
Sequencing in Newborn Screening Introduction and Background Suzanne Cordovado, PhD Newborn Screening and Molecular Biology Branch Division of Laboratory Sciences Centers for Disease Control and Prevention
More informationAssessing the follow-up of BART hemoglobin reported by the Wisconsin Newborn Screening Laboratory
Assessing the follow-up of BART hemoglobin reported by the Wisconsin Newborn Screening Laboratory Bao Yang MPH Candidate Background The Wisconsin Newborn Screening (NBS) Laboratory screens 70,000 babies
More informationNewborn bloodspot testing
Policy HUMAN GENETICS SOCIETY OF AUSTRALASIA ARBN. 076 130 937 (Incorporated Under the Associations Incorporation Act) The liability of members is limited RACP, 145 Macquarie Street, Sydney NSW 2000, Australia
More informationNewborn Metabolic Screening Programme Annual Report
Newborn Metabolic Screening Programme Annual Report January to December 2015 Disclaimer This publication reports on information provided to the Ministry of Health by the Auckland District Health Board.
More informationPurpose. Newborn Screening- UC 260. What is NBS? What isn t NBS? History. History 2
Purpose Newborn Screening- UC 260 Edward B. Goldman, J.D. Health System Attorney University of Michigan November 13, 2003 We will review newborn screening (NBS) history Look at current NBS practices Discuss
More informationNEWBORN SCREENING. in Massachusetts: Information for You and Your Baby. University of Massachusetts Medical School
University of Massachusetts Medical School NEWBORN SCREENING in Massachusetts: Information for You and Your Baby New England Newborn Screening Program Biotech 4, 2nd Floor UMass Medical School 377 Plantation
More informationBiochemical Genetics
Biochemical Genetics Laboratory Handbook 20010/11 Block 20 St James s Hospital Beckett Street Leeds LS9 7TF Introduction The Biochemical Genetics service is comprised of two regional laboratories, screening
More informationMISSOURI DEPARTMENT OF HEALTH AND SENIOR SERVICES
NEWBORN SCREENING Protecting your newborn MISSOURI DEPARTMENT OF HEALTH AND SENIOR SERVICES [ 1 ] NEWBORN SCREENING [ 2 ] FREQUENTLY ASKED QUESTIONS [ 4 ] DISORDERS INCLUDED IN NEWBORN SCREENING [ 12 ]
More informationInformation for health professionals
Changes to the Newborn Bloodspot Screening Policy for Congenital Hypothyroidism (CHT) in Preterm Babies A UK policy change has been agreed that will mean changes to: which preterm babies require second
More informationNeonatal Screening of Inborn Errors of Metabolism Using Tandem Mass Spectrometry
Ontario Health Technology Assessment Series 2003; Vol. 3, No. 3 Neonatal Screening of Inborn Errors of Metabolism Using Tandem Mass Spectrometry An Evidence-Based Analysis May 2003 \ Medical Advisory Secretariat
More informationFurther expansion of the neonatal screening panel in the Netherlands
Further expansion of the neonatal screening panel in the Netherlands J.Gerard Loeber APHL-NBSGT, St.Louis (MO), USA 290216 Population Area Newborns 6.01 million 0.35:1 16.8 million 180,693 sq km 4.3:1
More informationNewborn Screening in Japan: Restructuring for the New Era
Plenary 13 Newborn Screening in Japan: Restructuring for the New Era Seiji Yamaguchi, 1 MD Abstract Nationwide neonatal mass screening for inherited metabolic diseases has started in Japan since 1977.
More informationMetabolic Changes in ASD. Norma J. Arciniegas, MD Simón E. Carlo, MD Instituto Filius
Metabolic Changes in ASD Norma J. Arciniegas, MD Simón E. Carlo, MD Instituto Filius 12 patients 3 Autism: Ages 3/3/3.7 3 PDD: Ages 3/3/6 3 Asperger: Ages 6/7/15.1 3 Speech delay and Sensory Problems (SHL):
More informationAnnual Report Calendar Year 2015
Annual Report Calendar Year 2015 Page 1 of 19 Contents 1. SAMPLE VOLUMES IN 2015...3 1.1 SCREENING SAMPLES...3 1.1.1 INFANTS SCREENED...3 1.1.2 DECLINED/DEFERRED TESTING...4 1.1.3 MISSED SCREENS...5 1.2
More informationLynne A. Wolfe, MS, ACNP, PNP, BC Department of Genetics Yale School of Medicine
Lynne A. Wolfe, MS, ACNP, PNP, BC Department of Genetics Yale School of Medicine Harvey Levy, MD Mark Korson, MD Piero Rinaldo, MD, PhD Larry Sweetman, PhD K. Michael Gibson, PhD Charlie Roe, MD Jerry
More informationPKU gel Unflavored 1 year and older Powder 30x24g packets B4162
Reimbursement Codes The following information is provided to assist you with obtaining insurance reimbursement for Vitaflo products. Individual coverage varies by state and provider. Please contact your
More informationNEWBORN SCREENING. health.mo.gov/newbornscreening MISSOURI DEPARTMENT OF HEALTH AND SENIOR SERVICES
NEWBORN SCREENING health.mo.gov/newbornscreening MISSOURI DEPARTMENT OF HEALTH AND SENIOR SERVICES Table of Contents NEWBORN SCREENING...1 FREQUENTLY ASKED QUESTIONS...2 DISORDERS INCLUDED IN NEWBORN SCREENING...4
More informationMS/MS APPROACHES TO CLINICAL TESTING FOR INBORN ERRORS OF METABOLISM
MS/MS APPROACHES TO CLINICAL TESTING FOR INBORN ERRORS OF METABOLISM Tina M. Cowan, PhD Director, Clinical Biochemical Genetics Laboratory Stanford University Medical Center Presented at the 2011 Stanford
More informationSUMMARY THE RELEVANCE OF THE NEONATAL URINE SCREENING FOR INBORN ERRORS OF METABOLISM PERFORMED IN QUÉBEC. Introduction
SUMMARY THE RELEVANCE OF THE NEONATAL URINE SCREENING FOR INBORN ERRORS OF METABOLISM PERFORMED IN QUÉBEC Introduction Screening newborns for a number of hereditary diseases is common practice throughout
More informationHealth and Wellness for all Arizonans. azdhs.gov
To identify newborns with certain, rare disorders and assist families of affected infants so that they receive appropriate and timely treatment to prevent or delay serious medical problems. To identify
More informationMI Newborn Screening Program: An Overview of Follow-up & Case Management for Sickle Cell Conditions
Michigan Department of Community Health MI Newborn Screening Program: An Overview of Follow-up & Case Management for Sickle Cell Conditions Dominic Smith, MSA - Linda Carter, BSW - Ben Frazier, BSW - Ruth
More informationNewborn Metabolic Screening Programme. Annual Report
Newborn Metabolic Screening Programme Annual Report January to December 2016 1 Disclaimer This publication reports on information provided to the Ministry of Health by the Auckland District Health Board.
More informationMedical Foods for Inborn Errors of Metabolism
Medical Foods for Inborn Errors of Metabolism Policy Number: Original Effective Date: MM.02.014 02/18/2000 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 08/23/2013 Section: Medicine Place(s)
More informationNewborn Bloodspot Screening (NBS) Training for Health Visitors. December 2017
Newborn Bloodspot Screening (NBS) Training for Health Visitors www.newbornbloodspotscreening.wales.nhs.uk December 2017 Aims To enable you to gain a clear understanding of the following: Aim and rationale
More informationNewborn Screening Improving Children s Health
Newborn Screening Improving Children s Health By Frans Sardi Satyawirawan* Ina Susianti Timan ** * Dep. Of Clinical Pathology, Cipto Mangunkusumo Hospital (1974-2006) **Dep. of Clinical Pathology, Cipto
More informationFlow of samples and information for newborn screening in a model of publicprivate
Flow of samples and information for newborn screening in a model of publicprivate partnership Marzia Pasquali, PhD, FACMG Associate Professor of Pathology, University of Utah Medical Director, Biochemical
More informationArizona Newborn Screening Program
ARIZONA DEPARTMENT OF HEALTH SERVICES BUREAU OF STATE LABORATORY SERVICES Arizona Newborn Screening Program GUIDELINES DIVISION OF PUBLIC HEALTH SERVICES AUGUST 2010 with revisions (January 2011) Table
More informationNutritional Management of Inborn Errors of Metabolism. Kay Davis, RD, CSP Esther Berenhaut, RD, CSP, CSR Aug 28, 2017
Nutritional Management of Inborn Errors of Metabolism Kay Davis, RD, CSP Esther Berenhaut, RD, CSP, CSR Aug 28, 2017 OBJECTIVES Brief overview of newborn screening of metabolic disorders, inheritance patterns.
More informationInborn Errors of Metabolism From Neonatal Screening to Metabolic Pathways
19 May 2015 Hospital Authority Convention 2015 Corporate Scholarship Presentation II Paediatric Services Inborn Errors of Metabolism From Neonatal Screening to Metabolic Pathways Dr Grace Poon Associate
More informationWashington State Newborn Screening
Washington State Newborn Screening SAVING LIVES WITH A SIMPLE BLOOD SPOT WA State DOH 1 Washington State Numbers 1 2 173,000 specimens 90,000 newborns 2-screen state NBS 17 lab staff 5 disorder FU staff
More informationPilot Study of Newborn Screening (NBS) for Inborn Errors of Metabolism (IEM) in Collaboration with Department of Health and Hospital Authority
HA Convention 2017 Service Enhancement Presentation Healthcare Advances, Research and Innovations Pilot Study of Newborn Screening (NBS) for Inborn Errors of Metabolism (IEM) in Collaboration with Department
More informationAssessing Mothers Knowledge of the Wisconsin Newborn Screening Program. Sara Wolfgram UW Master of Public Health Symposium August 11, 2006
Assessing Mothers Knowledge of the Wisconsin Newborn Screening Program Sara Wolfgram UW Master of Public Health Symposium August 11, 2006 Background Wisconsin Newborn Screening (NBS): Began in 1965 Heel
More informationFor the Ongoing Management of Babies under 1 year old.
Pathway Author: Nicy Turney, Senior Nurse Professional Lead, Health Visiting 19.06.17 For the Ongoing Management of Babies under 1 year old. Check Health Records (CHR) to undertake daily checks to identify:
More informationquantifying allo-ile. Clinical Chemistry 54: (2008)
Clinical Chemistry 54:3 542 549 (2008) Pediatric Clinical Chemistry Second-Tier Test for Quantification of Alloisoleucine and Branched-Chain Amino Acids in Dried Blood Spots to Improve Newborn Screening
More informationShort and Long Term Stability of 3-Hydroxy acylcarnitines Enriched Dried Blood Spots Stored at Various Temperatures and Humidities
Short and Long Term Stability of 3-Hydroxy acylcarnitines Enriched Dried Blood Spots Stored at Various Temperatures and Humidities Timothy Lim Biochemical Mass Spectrometry Laboratory Newborn Screening
More informationWHO Growth Grids/ 2012 Risk Changes. Diane Traver Joyce Bryant
WHO Growth Grids/ 2012 Risk Changes Diane Traver Joyce Bryant Overview CDC vs WHO Growth Charts- Why Change? Transition from
More informationWhat s new in newborn screening?
PERSPECTIVE What s new in newborn screening? Bradford L Therrell Jr 1,2, Colleen Buechner 1,2, Michele A Lloyd-Puryear 3,4, Peter C van Dyck 3,5 & Marie Y Mann 3,6 Author for correspondence 1 National
More informationProposal for EXPANDED NEWBORN SCREENING
Proposal for EXPANDED NEWBORN SCREENING Tel:+971-4-4503875 Fax:+971-4-4503874 DuBiotech, P.O.Box 212671Dubai, UAE. Email: info@easternbiotech.com www.easternbiotech.com Winner of Dubai SME100 Ranked #19
More informationPast, present and future of newborn screening in Chile
DOI 10.1007/s10545-010-9165-8 RESEARCH REPORT Past, present and future of newborn screening in Chile V. Cornejo & E. Raimann & J. F. Cabello & A. Valiente & C. Becerra & M. Opazo & M. Colombo Received:
More informationInborn Errors of Metabolism (IEM)
Clinical Presentation Inborn Errors of Metabolism (IEM) Click on the following: - Clinical Pearl - link to movie clip - link to picture Investigations Blood Work Urine No Acidosis NH 4 + Metabolic Acidosis
More informationSlide 1: Newborn Bloodspot Screening for Medium-chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
Slide 1: Newborn Bloodspot Screening for Medium-chain Acyl-CoA Dehydrogenase Deficiency (MCADD) The information has been produced with thanks to the NHS Newborn Blood Spot Screening Programme. 1 Slide
More informationNewborn Metabolic Screening Programme
Newborn Metabolic Screening Programme Annual Report January to December 2017 Released 2018 health.govt.nz Disclaimer This publication reports on information provided to the Ministry of Health by the Auckland
More informationAcylcarnitine measurement in blood spots: methodological aspects, problems and pitfalls with reference to the ERNDIM QA scheme
Acylcarnitine measurement in blood spots: methodological aspects, problems and pitfalls with reference to the ERNDIM QA scheme Charles Turner Laboratory Guy s Hospital (Evelina Childrens Hospital, St Thomas
More informationA Brief History of Newborn Screening
A Brief History of Newborn Screening The first 50 years. Ken Pass I didn t do this alone Thanks to: Amy Hoffman Alex Kemper Kathy Harris Piero Rinaldo and others 1902 Liv Dag Asbjorn Follin Pediatrics
More informationHistory of Metabolic Tests. Dr Mick Henderson Biochemical Genetics Leeds and Manchester
History of Metabolic Tests Dr Mick Henderson Biochemical Genetics Leeds and Manchester This presentation Wont just be a history lesson But there will be some of that! Hopefully will give an impression
More informationShort Term Follow Up Tandem Mass Spectrometry Workshop Agenda
Short Term Follow Up Tandem Mass Spectrometry Workshop Agenda June 11-15, 2018 APHL Headquarters 8515 Georgia Ave Silver Spring, MD 20910 This meeting is sponsored by the Association of Public Health Laboratories
More informationBROADENING YOUR PATIENT S OPTIONS FOR GENETIC CARRIER SCREENING.
BROADENING YOUR PATIENT S OPTIONS FOR GENETIC CARRIER SCREENING. The Inheritest SM Carrier Screen provides relevant genetic screening for many inherited diseases found throughout the pan-ethnic US population.
More informationNewborn Screening and Genetic Testing Michele A. Lloyd-Puryear, MD, PhD, FAAP, Irene Forsman, RN, MS
CLINICAL ISSUES Newborn Screening and Genetic Testing Michele A. Lloyd-Puryear, MD, PhD, FAAP, Irene Forsman, RN, MS Mandated newborn screening programs for genetic and other congenital conditions for
More informationSaudi Population & Genetic Diseases
CHALLENGES TO TREATMENT OF INHERITED METABOLIC DISORDES: THE SAUDI EXPEREINCE Zuhair N. Al-Hassnan, MD Dept. of Medical Genetics, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
More informationNewborn Screen & Development Facts about the genetic diseases new since March 2006 (Excluding Cystic Fibrosis)
Newborn Screen & Development Facts about the genetic diseases new since March 2006 (Excluding Cystic Fibrosis) 1) Argininosuccinic acidemia (ASA) a) Incidence: ~1 in 70,000 b) Deficiency in an enzyme of
More informationAtlas of Genetics and Cytogenetics in Oncology and Haematology
Atlas of Genetics and Cytogenetics in Oncology and Haematology Neonatal Screening I - INTRODUCTION 1- Neonatal screening for a metabolic disease must address a frequent pathology for which there is an
More informationLecture 10 - Protein Turnover and Amino Acid Catabolism
Lecture 10 - Protein Turnover and Amino Acid Catabolism Chem 454: Regulatory Mechanisms in Biochemistry University of Wisconsin-Eau Claire 1 Introduction 2 Proteins are degraded into amino acids. Protein
More informationSimultaneous Analysis of Amino Acids and Acylcarnitines in Dried Blood Spots
Simultaneous Analysis of Amino Acids and Acylcarnitines in Dried Blood Spots Application Note Authors M.P. George Alere Toxicology Services Gretna, LA USA David Presser Agilent Technologies, Inc Santa
More informationNewborn Screening by Tandem
Newborn Screening by Tandem Mass Spectrometry in Texas Patricia Hunt Manager, Newborn Metabolic Screening Group Biochemistry and Genetics Branch Texas Department of State Health Services May 30, 2012 Texas
More informationPiero Rinaldo, Si Houn Hahn, Dietrich Matern. Biochemical Genetics Laboratory Mayo Clinic College of Medicine Rochester, MN
Improved Specificity of Newborn Screening for Congenital Adrenal Hyperplasia (CAH) by Second Tier Steroid Profiling using Tandem Mass Spectrometry (MS/MS) Piero Rinaldo, Si Houn Hahn, Dietrich Matern Biochemical
More information